Ayala Pharmaceuticals Inc (ADXS)

[Zoltarak]

Agreed Blue. I'm hoping that this team can get the company through an EMA approval, w/o further dilution. From there, the valuation should be north of 2 billion for starters, since approval would be a strong validator of the platform. Then, let some BPs poke around and take notice. Throw in the NEO potential and somebody may pay north of 4B over the entire enchilada.

All of this can happen before summer of 2019. Going to be quite interesting from here on out, especially when that hold is lifted.